Skip to main content
Premium Trial:

Request an Annual Quote

Signature Dx to Use Affymetrix Chips for Cancer Test Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix and Signature Diagnostics today announced that they have inked an agreement under which Signature Dx has gained a worldwide license to use Affymetrix's microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer tests.

Potsdam, Germany-based Signature Dx intends to launch two microarray-based IVD tests by the fourth quarter of this year for colorectal cancer, the firms said. Signature will first launch the tests in Europe and intends to seek US regulatory approval at an unspecified time in the future.

Signature has been developing the tests, called Detector C and Predictor C. Detector C is a non-invasive, blood-based early detection test that the firm said has shown 90 percent sensitivity and 88 percent specificity for all four stages of colorectal cancer. Predictor C is a tissue test that predicts disease progression in stage II and III colorectal cancer patients and has been shown to identify half of all stage II/III patients with a high risk of disease progression.

"Our novel Detector C blood screening product together with Affymetrix's gene expression array technology brings CRC screening to a new level of accuracy and sensitivity," André Rosenthal, CEO of Signature Diagnostics, said in a statement.

Financial terms of the agreement were not disclosed.

The deal is part of Affy's 'Powered by Affymetrix's partnering program.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more